DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Neostigmine Methylsulfate is a drug marketed by Am Regent, Amneal, Amphastar Pharms Inc, Amring Pharms, Be Pharms, Dr Reddys, Eurohlth Intl Sarl, Fresenius Kabi Usa, Gland Pharma Ltd, Hong Kong, and Par Sterile Products. and is included in eleven NDAs.
The generic ingredient in NEOSTIGMINE METHYLSULFATE is neostigmine methylsulfate. There are nine drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the neostigmine methylsulfate profile page.
A generic version of NEOSTIGMINE METHYLSULFATE was approved as neostigmine methylsulfate by FRESENIUS KABI USA on January 8th, 2015.
Summary for NEOSTIGMINE METHYLSULFATE
|Finished Product Suppliers / Packagers:||12|
|Raw Ingredient (Bulk) Api Vendors:||90|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for NEOSTIGMINE METHYLSULFATE|
|What excipients (inactive ingredients) are in NEOSTIGMINE METHYLSULFATE?||NEOSTIGMINE METHYLSULFATE excipients list|
|DailyMed Link:||NEOSTIGMINE METHYLSULFATE at DailyMed|
Recent Clinical Trials for NEOSTIGMINE METHYLSULFATE
Identify potential brand extensions & 505(b)(2) entrants
|Fondazione Policlinico Universitario Agostino Gemelli IRCCS||N/A|
|Fayoum University Hospital||Phase 4|
|Emory University||Early Phase 1|